Company intelligence / Profile preview
Silence Therapeutics
London, London, United Kingdomsilence-therapeutics.com ↗
- Ownership
- Public · SLN
- Employees
- ~116
- Development stage
- Phase 2
01
Overview
Phase 1 study of zerlasiran (SLN360) showed injection of repeated doses reduced patients' baseline of Lp(a) by up to 99 per cent for 90 days after administration
- Therapeutic areas
- Rare DiseasesHematologyGastroenterologyCardiovascular
- Modalities
- siRNA (short interfering RNA)RNA interference (RNAi)
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Request access →03
Partnerships
AstraZeneca PLCMallinckrodt PharmaceuticalsHansoh Pharma
04
Financials
- Market cap
- $640M
- Total revenue
- $0
- Enterprise value
- $568.1M
Beyond the preview
Go deeper on Silence Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Silence Therapeutics.